Latest Intelligence on Biotechnology in Austria

Select information type

Refine your search

Search tips

Published within

« | 1 | » »|

Type Product title / description Pub Price

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008

« | 1 | » »|

No help is available.